

**Therapies for Children with Autism Systematic Evidence Review**  
**Full Text Review Form**

First Author, Year: \_\_\_\_\_ Reference ID #: \_\_\_\_\_ Abstractor Initials: \_\_\_\_\_

1. Includes participants <b>ages 2-12 diagnosed with ASD</b> (Autism, Aspergers, PDD-NOS) OR <b>0-2 at risk</b>	Yes	No
a. If study includes participants >12yrs, record mean age+SD: _____. Circle <b>Yes</b> if mean age+SD $\leq$ 12.		
2. Original research (exclude editorials, commentaries, letters, reviews, etc.)	Yes	No
3. Eligible study size (circle <b>Yes</b> if $N \geq 10$ <b>TOTAL</b> age 2-12 with ASD or at risk OR with mean age+SD $\leq$ 12) a. if No, record N: _____	Yes	No
4. Does the study address one or more of the following questions (check applicable KQ below):	Yes	No

\_\_\_KQ1: Among children ages 2-12 with ASD, what are the short and long-term effects of available behavioral, educational, family, medical, allied health, or CAM treatment approaches?

**Treatment studied (circle applicable:** medical, educational, allied health, CAM, behavioral )

**SPECIFY INTERVENTION** \_\_\_\_\_

\_\_\_KQ1a: What are the effects on core symptoms (e.g. social deficits, communication deficits and repetitive behaviors), in the short term ( $\leq$ 6 months)?

\_\_\_KQ1b: What are the effects on commonly associated symptoms (e.g. motor, sensory, medical, mood/anxiety, irritability, IQ/cognition, and hyperactivity) in the short term ( $\leq$ 6 months)?

\_\_\_KQ1c: What are the longer-term effects ( $>$ 6 mos) on core symptoms (e.g. social deficits, communication deficits and repetitive behaviors)?

\_\_\_KQ1d: What are the longer-term effects ( $>$ 6 mos) on commonly associated symptoms (e.g. motor, sensory, medical, mood/anxiety, irritability, IQ/cognition, and hyperactivity)?

\_\_\_KQ2: Among children ages 2-12, what are the modifiers of outcome for different treatments or approaches?

\_\_\_KQ2a: Is the effectiveness of the therapies reviewed affected by the frequency, duration, and intensity of the intervention?

\_\_\_KQ2b: Is the effectiveness of the therapies reviewed affected by the training and/or experience of the individual providing the therapy?

\_\_\_KQ2c: What characteristics, if any, of the child modify the effectiveness of the therapies reviewed?

\_\_\_KQ2d: What characteristics, if any, of the family modify the effectiveness of the therapies reviewed?

\_\_\_KQ3: Are there any identifiable changes early in the treatment phase that predict treatment outcomes?

\_\_\_KQ4: What is the evidence that effects measured at the end of the treatment phase predict long term functional outcomes?

\_\_\_KQ5: What is the evidence that specific intervention effects measured in the treatment context generalize to other contexts (e.g., people, places, materials)?

\_\_\_KQ6: What evidence supports specific components of treatment as driving outcomes, either within a single treatment or across treatments?

\_\_\_KQ7: What evidence supports the use of a specific treatment approach in children under the age of 2 who are at high risk of developing autism based upon behavioral, medical, or genetic risk factors?

5. Study published in English	Yes	No
-------------------------------	-----	----

*EXCLUDE IF AN ITEM IN A GRAY BOX IS SELECTED*

6. Review the reference list (included papers only) and list author name/year for EPC to verify if included in database:

---

---

---

7. If excluded, retain for \_\_\_\_\_ Background/Discussion \_\_\_\_\_ Other: \_\_\_\_\_

**Comments:**